The company is substantially boosted the course of an novel therapy for ATTR-CM, leveraging the investigational drug. Initial clinical results suggests significant improvements for those diagnosed with this debilitating https://bridgebio839309.blogdeazar.com/42502621/bridgebio-advances-amyloidosis-treatment-through-the-therapy